NCT02034123View on ClinicalTrials.gov

Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

February 4, 2014

Primary Completion Date

April 18, 2017

Study Completion Date

April 18, 2017

Conditions
Carcinoma, Small Cell
Interventions
DRUG

GSK2879552

Subjects will receive GSK2879552orally with approximately 200 milliliter (mL) of water.

Trial Locations (8)

28034

GSK Investigational Site, Madrid

28040

GSK Investigational Site, Madrid

29010

GSK Investigational Site, Málaga

37203

GSK Investigational Site, Nashville

43210

GSK Investigational Site, Columbus

63110

GSK Investigational Site, St Louis

94805

GSK Investigational Site, Villejuif

08035

GSK Investigational Site, Barcelona

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02034123 - Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma | Biotech Hunter | Biotech Hunter